Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of UGT2B7*2 polymorphism on the pharmacokinetics of OROS® hydromorphone in Taiwanese subjects.

Journal of clinical pharmacology - 1 Oct 2014

Vandenbossche Joris, Richards Henry, Francke Stephan, Van Den Bergh An, Lu Chih Cherng, Franc Monique A

Abstract excerpt

This open-label, single-center, phase I study (NCT1487564) investigated the effect of uridine diphosphate-glucuronosyltransferase2B7 (UGT2B7*2) genetic polymorphism (H268Y) on the pharmacokinetics (PK) and safety of a single, oral, 16-mg dose of OROS® hydromorphone and its metabolite in healthy Taiwanese subjects. Plasma concentrations of hydromorphone and hydromorphone-3-glucuronide were determined in 28...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asian People

Share to Delayed-Action Preparations

Share to Glucuronates

Share to Glucuronosyltransferase

Share to Naltrexone

Share to Taiwan

Source

Identifiers

PMID: 24706503
DOI: 10.1002/jcph.305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of UGT2B7*2 polymorphism on the pharmacokinetics of OROS® hydromorphone in Taiwanese subjects.PMID 24706503Read ↗

Exploratory study on association of single-nucleotide polymorphisms with hydromorphone analgesia in ED.Semantic proximity Read ↗

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.Semantic proximity Read ↗

The Role of Clinical Pharmacogenetics and Opioid Interactions in Optimizing Treatment in Clinical PracticeSemantic proximity Read ↗

The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin.Semantic proximity Read ↗

Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).Semantic proximity Read ↗

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.Semantic proximity Read ↗

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.Semantic proximity Read ↗

Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.Semantic proximity Read ↗

Genetic polymorphism of UDP-glucuronosyltransferase (UGT2B15) and glucuronidation of paracetamol in healthy population.Semantic proximity Read ↗

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.Semantic proximity Read ↗

A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure.Semantic proximity Read ↗

Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.